SAN DIEGO / Aug 05, 2025 / Business Wire / Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
Canaccord Genuity 45th Annual Growth Conference
Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET
Citi's 2025 Biopharma Back to School Conference
Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET
2025 Wells Fargo Healthcare Conference
Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET
Cantor Global Healthcare Conference 2025
Presenting on Thursday, September 4, 2025, at 2:45 p.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit www.travere.com.
Last Trade: | US$17.39 |
Daily Change: | -0.24 -1.36 |
Daily Volume: | 42,279 |
Market Cap: | US$1.550B |
June 03, 2025 May 15, 2025 April 29, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load